Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2016-2023
The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.
This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2016 to 2023.
For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.
Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.
Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 6 provides a review of the top 25 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2016.
In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.
Key benefits
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides the reader with the following key benefits:
- In-depth understanding of co-promotion and co-marketing deal trends since 2016
- Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
- Comprehensive access to over 400 actual co-promotion and co-marketing deals entered into by the world’s biopharma companies
- Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes:
- Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2016
- Analysis of co-promotion and co-marketing deal structure
- Case studies of real-life co-promotion and co-marketing deals
- Access to over 400 co-promotion and co-marketing deal records
- Detailed access to actual co-promotion contract documents
- The leading co-promotion and co-marketing deals by value since 2016
- Most active co-promotion and co-marketing dealmakers since 2016
- The leading co-promotion and co-marketing partnering resources
In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology area
Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to records for over 400 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise co-promotion and co-marketing rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2016-2023 provides the reader with the following key benefits:
- In-depth understanding of co-promotion and co-marketing deal trends since 2016
- Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies
- Comprehensive access to over 400 co-promotion and co-marketing deals entered into by the world’s biopharma companies, together with contract documents if available
- Detailed access to actual co-promotion and co-marketing contracts entered into by the leading big pharma and big biotech companies
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- Identify leading co-promotion and co-marketing deals by value since 2016
- Identify the most active co-promotion and co-marketing dealmakers since 2016
- Full listing of co-promotion and co-marketing deals by company A-Z, headline value, phase of development, deal type, therapy and technology focus
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in co-promotion and co-marketing dealmaking
2.1. Introduction
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2016
2.3.1. Co-promotion and co-marketing dealmaking by year, 2016 to 2023
2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2016 to 2023
2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2016 to 2023
2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2016 to 2023
2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2016 to 2023
2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2016 to 2023
2.4. When co-marketing can be useful
2.5. When co-marketing is the only option
2.6. Pure deals and multi-component deals
2.6.1. Attributes of pure co-promotion deals
2.6.2. Attributes of co-promotion in multi-component deals
2.7. Reasons for including co-promotion options in a deal
2.8. Uptake of co-promotion rights
2.9. Co-promotion rights as bargaining chips
2.10. Aligning partners to make the co-promote work
Chapter 3 – Overview of co-promotion deal structure
3.1. Introduction
3.2. Pure versus multi-component co-promotion deals
3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1
3.3.1.b. Case study 2
3.4. Co-promotion rights as part of a wider alliance agreement
3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3
3.4.1.b. Case study 4
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5
3.4.2.b. Case study 6
3.5. Embedded co-promotion rights enabling third party engagement
3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7
Chapter 4 – Overview of co-marketing deal structure
4.1. Introduction
4.2. Co-marketing agreement structure
4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8
4.3. Co-marketing rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9
Chapter 5 – Leading co-promotion and co-marketing deals
5.1. Introduction
5.2. Top co-promotion and co-marketing deals by value
Chapter 6 – Top 25 most active co-promotion and co-marketing dealmakers
6.1. Introduction
6.2. Top 25 most active co-promotion and co-marketing dealmakers
Chapter 7 – Co-promotion and co-marketing agreement contracts directory 2016 - 2023
7.1. Introduction
7.2. Co-promotion and co-marketing deals with contracts 2016 to 2023
Appendices
Appendix 1 – Co-promotion and co-marketing deals by company A-Z
Appendix 2 – Co-promotion and co-marketing deals by stage of development
Appendix 3 – Co-promotion and co-marketing deals by deal type
Appendix 4 – Co-promotion and co-marketing deals by therapy area
Appendix 5 – Co-promotion and co-marketing deals by technology type
Appendix 6 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion and co-marketing deal announcements, 2016 to 2023
Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2016 to 2023
Figure 4: Co-promotion and co-marketing deals by industry sector, 2016 to 2023
Figure 5: Co-promotion and co-marketing deals by therapy area, 2016 to 2023
Figure 6: Co-promotion and co-marketing deals by technology type, 2016 to 2023
Figure 7: Top 25 most active co-promotion and co-marketing dealmakers, 2016 to 2023
Figure 8: Situations where co-marketing can prove useful
Figure 9: Key components of a pure co-promotion deal
Figure 10: Key components of a multi-component co-promotion deal
Figure 11: Example deals where co-promotion options have been actively exercised, since 2000
Figure 12: Issues in implementing co-promotion agreements
Figure 13: Co-promotion agreements – what should a contract include?
Figure 14: Components of the co-promotion deal structure
Figure 15: Components of the co-marketing deal structure
Figure 16: Top co-promotion and co-marketing deals by value since 2016
Figure 17: Most active co-promotion and co-marketing dealmakers 2016 to 2023
Pricing options
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by SagePay.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3D Medicines, 7D Surgical, 10X Genomics, Abbvie, Abveris, ACADIA Pharmaceuticals, Acceleron Pharma, Accent Therapeutics, Accinov, ACEA Biosciences, Acelrx Pharmaceuticals, Acerus, AC Immune, ACIST Medical Systems, Adaptimmune, Adhera Therapeutics, Advanced Analytical Technologies, Aesculap, AEterna Zentaris, Affibody, Affini-T Therapeutics, Agena Bioscience, Agenus Bio, Agilent Technologies, Aignostics, AiLife Diagnostics, AirXpanders, Ajinomoto, Akeso Biopharma, Akoya Biosciences, Albany Molecular Research, Alector, Alexion Pharmaceuticals, Alfasigma, ALK-Abello, Allcyte, Allegis Pharmaceuticals, Allergan, Almirall, Alphazyme, Alyvant, Amgen, Amneal Pharmaceuticals, AMRA, AMRA Medical, Analytik Jena, Andrew Alliance, AnGes MG, Apellis Pharmaceuticals, Applied Cells, Applied DNA Sciences, Applied Spectral Imaging, Aratana Therapeutics, Arcellx, ArcherDX, Arcis Biotechnology, Arcturus Therapeutics, Arcus Biosciences, argenx, Argonaut Manufacturing Services, Aries Pharmaceuticals, Arima Genomics, Arkema, Armune Bioscience, ArQule, Arrowhead Pharmaceuticals, Arvinas, Ascend Therapeutics, Ascentage Pharma, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Aurora Spine, Automated Systems of Tacoma, Avid Bioservices, Axcend, Aytu BioPharma, Aziyo Biologics, Basilea Pharmaceutica, Bausch & Lomb, Baxalta, Bayer, B Braun, Beam Therapeutics, Beckman Coulter, Becton Dickinson, BeiGene, Beijing Minhai Biotechnology, Belharra Therapeutics, Belintra, Berlin Chemie, BGI, BGI Americas, BioAge Labs, Biocrates, Biodextris, BioFluidica, Biogen, Biognosys, Biological Industries, BioNano Genomics, BioNTech, Biosero, BioTek Instruments, Blake Insomnia Therapeutics, Bluebird Bio, Blueprint Medicines, Boehringer Ingelheim, Bolt Biotherapeutics, Bond Digital Health, BOWA Medical, Bracco Imaging, BrainLAB, BridgeBio Pharma, Bristol-Myers Squibb, Brooks Life Science Systems, Bruker, Burning Rock, Cambrooke Therapeutics, Capsida Biotherapeutics, Carl Zeiss, CathWorks, CC Pharma, Celgene, Cellectricon, Cellenion, Cell Guidance Systems, Cellular Dynamics International, Centogene, Century Therapeutics, Cevec Pharmaceuticals, Chime Biologics, Cipher Pharmaceuticals, Clarify Medical, Clearbridge Biomedics, CloudHealth Genomics, COBO Technologies, Codexis, CompleWare, Concordia Pharmaceuticals, Consortia Health, Corazon, CRISPR Therapeutics, CSL, CStone Pharmaceuticals, Cue Biopharma, Cullinan Oncology, Cumberland Pharmaceuticals, CureVac, Curio Genomics, Cyclica, Cynergi Health Partners, CytomX Therapeutics, CytoSorbents, Daiichi Sankyo, Delic, Denali Therapeutics, DePuy, DexCom, Diabetes Tools, Dicerna Pharmaceuticals, Domainex, Dova Pharmaceuticals, Dovetail Genomics, Eagle Genomics, Eagle Pharmaceuticals, EA Pharma, eCential Robotics, Echolight Medical, Eckert & Ziegler, ECMOHO, eFFECTOR Therapeutics, Egalet, Eigen, Eiger BioPharmaceuticals, Eisai, Elanco, Elekta, Element Biosciences, Eli Lilly, Elucidata, Empatica, Enterome Bioscience, EOS Imaging, Epicypher, Epizyme, EPS International, Eton Pharmaceuticals, Everledger, Evosep, eWellness Healthcare, Exact Sciences, Fabric Genomics, Fate Therapeutics, Ferring Pharmaceuticals, Fidelis Research, Fio, FlowJo, Fluidigm, Foghorn Therapeutics, Fortelinea Software Systems, Fosun International, Fosun Pharmaceutical, Freenome, Fresenius Medical Care, Fusion Pharmaceuticals, G1 Therapeutics, Galapagos, GANZIMMUN Diagnostics, GE Healthcare, Gencove, Genentech, Genetron Health, Genialis, Genmab, Genoox, Genosity, GenScript Biotech, George Clinical, Getein Biotech, Gilead Sciences, GlaxoSmithKline, Glenmark Pharmaceuticals, Goldfinch Bio, Great Bay Bio, GT Research, Guerbet, Guohong Guokang (Beijing) Health Technology Development, H3 Biomedicine, HalioDx, Halyard Health, Hamamatsu Photonics, Hamilton Company, Hanmi Pharmaceutical, Harbin Pharmaceutical Group, Harbour Antibodies, HD Biosciences, HeartGenetics, Heartseed, Helsinn Healthcare, Helsinn Therapeutics, Henkel, High Beauty, Hitachi Medical Systems Europe, Hormosan Pharma GmbH, Iagnosis, IBA, Ibex Medical Analytics, IBM Watson Health, Icagen, Iconic Therapeutics, IDbyDNA, Idorsia, Igentify, IGM Biosciences, Illumina, ImaBiotech, Immatics Biotechnologies, Immunicon, ImmunityBio, ImmunoGen, Immunomedics, Incyte, Indee Labs, Indegene Lifesystems, Indica Labs, Infinitt, Innara Health, Innate Pharma, Innovent Biologics, Inscopix, Insitro, Inspirion Delivery Sciences, Intabio, Integrated DNA Technologies, Intellia Therapeutics, Ionis Pharmaceuticals, IROA Technologies, iTeos Therapeutics, Janssen Biotech, Janssen Pharmaceuticals, Jiangsu Alphamab, Jiangsu Carephar Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Jointpoint, Joylux, Jumpcode Genomics, K2M, Kailos Genetics, Kaleo, Kerma Medical Products, Kite Pharma, Konica Minolta, Kowa Pharmaceuticals America, KSQ Therapeutics, KVP International, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyverna Therapeutics, L1 Systems, Leica Biosystems, Leica Microsystems, LEO Pharma, Lexington Medical, LG Life Sciences, Lord Global, Loxo Oncology, Lunaphore, Luqa Pharmaceuticals, Luxcel Biosciences, Lygos, Macherey-Nagel, Macrogenics, Magnolia Medical, Mainz Biomed, Malvern Instruments, Manchester BIOGEL, MannKind Biopharmaceuticals, Mazor Robotics, MedHelp, Medical Enterprises Distribution, Medicines360, Medigus, MedImmune, Medis, Medovate, Medtronic, Meihua International Medical Technologies, MEI Pharma, MeMed, Menarini, Menarini Silicon Biosystems, Merck and Co, Merck KGaA, Mersana Therapeutics, Mesoblast, Metagenomi, Metavant, MGI Tech, Microsaic Systems, Microsoft, Midatech, Miltenyi Biotec, Mission Bio, Mochida Pharmaceutical, Moderna, Molnlycke Health Care, Momenta Pharmaceuticals, Morphic Therapeutic, MorphoSys, MRM Proteomics, MSD, MYOS, Myovant Sciences, Nanion, NanoString Technologies, NantKwest, Napo Pharmaceuticals, Ncardia, Nestle Health Science, NeuPath Health, Neurexpert, Neurocrine Biosciences, Newomics, New York Center for Nanomedicine Research, Nexa3D, Nexel, Next&Bio, Nkarta Therapeutics, Noldus Information Technology, Novartis, Novogene, Novo Nordisk, Nrgene, Nucleai, Nurix, nView Medical, ODI Pharma, Olympus, Olympus Medical Systems, OncoSec Medical, ONK Therapeutics, Ono Pharmaceutical, OpGen, OptiNose, Orapharma, Orion, Ortho-Clinical Diagnostics, Orthofix Medical, Osteopore International, Otonomy, Otsuka, Oxford BioMedica, Pacific Biosciences, Pacira Biosciences, Paige, Paragon Bioservices, Pfizer, Pharmaceutics International, Phil, Pierian, PierianDx, Pieris Pharmaceuticals, Piramal, Pivot Pharmaceuticals, Poxel, Precision BioSciences, PrecisionLife, Predicine, Pressure BioSciences, Prevail Therapeutics, Protagonist Therapeutics, Protea Biosciences, Protean BioDiagnostics, Protein Metrics, Proteos, Proteovant Therapeutics, ProTom International, Provention Bio, PSI (Population Services International), Purdue Pharma, PureHoney Technologies, Pure Pharmaceuticals, QED Therapeutics, Qiagen, QMed Innovations, Quanta, Radformation, Radius Health, Rainbow Scientific, Rakuten Medical, RedHill Biopharma, RefleXion Medical, Regenxbio, Relay Medical, Relay Therapeutics, Repare Therapeutics, Resonant Specific Technologies, Revolution Medicines, Rigel Pharmaceuticals, Roche, Roche Diagnostics, Roivant Sciences, Royal Philips Electronics, Rubicon Genomics, S2 Genomics, Sage Therapeutics, Sajo Consulting, Salix Pharmaceuticals, Sanofi, Sanofi-Aventis, Sanofi US Services, Santen Pharmaceutical, Sarepta Therapeutics, Sato Pharmaceutical, Schrodinger, Sciex, Scorpion Therapeutics, Seagen, SeaSpine, Seattle Genetics, Senshinkai Eye Institute, Seren Pharmaceuticals, Seres Therapeutics, Shimadzu, Shionogi, Silicon Biosystems, Simcere Pharmaceuticals, Sirona Dx, Sirtex Medical, SK Biopharmaceuticals, Solid Biosciences, Sona Nanotech, Sosei, SoTAX, SparingVision, Spineart, SpiroChem, Staar Surgical Co, Stealth BioTherapeutics, Stoke Therapeutics, StrideBio, Stryker, STU, Sumitomo Dainippon Pharma, Summit Therapeutics, Sunovion Pharmaceuticals, Sun Pharmaceutical, SurGenTec, Surgical Planning Associates, Sutro Biopharma, Swift Biosciences, Swixx Biopharma, Synaptive Medical, Syndax Pharmaceuticals, Taiho, Taisho Pharmaceutical, Takeda Pharmaceutical, Tango Therapeutics, Teijin, Telix Pharmaceuticals, Terumo, Terumo Blood and Cell Technologies, Tetraphase Pharmaceuticals, Theravance, Thermo Fisher Scientific, Tilak Healthcare, Tilray, Tissue Analytics, Titan Pharmaceuticals, Tolmar, TOMI Environmental Solutions, TRACON Pharmaceuticals, Tractebel, TransMIT, Trovita Health Science, TTP LabTech, Twist Bioscience, Tyme Technologies, UCB, Ultivue, Ultragenyx Pharmaceuticals, Uni-Bio Science, Unisys, Universal Cells, Urovant Sciences, US WorldMeds, Verity Pharmaceuticals, Vertex Pharmaceuticals, Vertice Pharma, Vida Diagnostics, Vifor Pharma, Virscidian, Visiopharm, Voyager Therapeutics, Waters Corporation, WAVE Life Sciences, Wyatt Technology, Xellia Pharmaceuticals, Xencor, ZAI Laboratory, Ziath, Zimmer Biomet, Zymeworks
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
